Clinical Trial Update: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity [Phase 3]

View source ↗

Summary

This document notes a Phase 3 clinical trial (NCT07037433) evaluating Maridebart Cafraglutide for cardiovascular outcomes in adults with atherosclerotic cardiov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Obesity

Drugs mentioned

• Maridebart Cafraglutide

Snippet

Sponsor: Amgen | Conditions: Atherosclerotic Cardiovascular Disease, Overweight | Phase 3 | Status: RECRUITING